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Obesity is associated with development and progression of chronic kidney
disease (CKD). Recent evidence demonstrates that enhanced levels of the
L-arginine:ureahydrolase, including the two isoenzymes arginase-I (Arg-I) and arginase-II
(Arg-II) in vascular endothelial cells promote uncoupling of endothelial nitric oxide
synthase (eNOS), leading to increased superoxide radical anion and decreased NO
production thereby endothelial dysfunction. Arg-II but not Arg-I is abundantly expressed
in kidney and the role of Arg-II in CKD is uncertain and controversial. We aimed to
investigate the role of Arg-II in renal damage associated with diet-induced obesity mouse
model. Wild type (WT) C57BL/6 mice and mice deficient in Arg-II gene (Arg-II−/−) were
fed with either a normal chow (NC) or a high-fat-diet (HFD) for 14 weeks (starting at the
age of 7 weeks) to induce obesity. In WT mice, HFD feeding caused frequent renal lipid
accumulation, enhancement of renal reactive oxygen species (ROS) levels which could
be attenuated by a NOS inhibitor, suggesting uncoupling of NOS in kidney. HFD feeding
also significantly augmented renal Arg-II expression and activity. All the alterations in
the kidney under HFD feeding were reduced in Arg-II−/− mice. Moreover, mesangial
expansion as analyzed by Periodic Acid Schiff (PAS) staining and renal expression
of vascular adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1
(ICAM-1) in HFD-fed WT mouse assessed by immunoblotting were reduced in the
HFD-fed Arg-II−/− mice, although there was no significant difference in body weight
and renal weight/body weight ratio between the WT and Arg-II−/− mice. Thus, Arg-II
expression/activity is enhanced in kidney of diet-induced obesity mice. Genetic targeting
of Arg-II prevents renal damage associated with obesity, suggesting an important role of
Arg-II in obesity-associated renal disease development.
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INTRODUCTION
According to the latest Non-Communicable Diseases Risk-
Factor Collaboration (NCD-RisC) report, in 2014 there were
422 million people worldwide who had diabetes, i.e., roughly a
four-fold increase over the past 35 years (Collaboration, 2016).
Diabetic nephropathy or diabetic chronic kidney disease (CKD)
is one of the important diabetic complications representing the
most common cause of end-stage renal disease (Collins et al.,
2013). Although the mechanisms underlying obesity-associated
diabetic renal damage are complex and have not yet been fully
understood, it has been demonstrated that ectopic renal lipid
accumulation, inflammation including macrophage infiltration
in kidney through adhesion molecules, i.e., vascular adhesion
molecule-1 (VCAM-1) and intercellular adhesion molecule-
1 (ICAM-1), glomerulus mesangial expansion, impaired
endothelial nitric oxide (NO) bioavailability and oxidative stress
or increased ROS generation in kidney are importantly involved
in the development of diabetic renal damage (Nakagawa et al.,
2011).
There are studies showing key roles of endothelial nitric
oxide synthase (eNOS) in protection against development of
diabetic renal disease (Wang et al., 2011; Cheng et al., 2012;
Cheng and Harris, 2014). Functional alteration of eNOS, in
particular, eNOS-uncoupling, a situation that eNOS enzyme
produces more superoxide radical anion instead of NO, has
been shown to be critical in endothelial dysfunction and diabetic
renal disease (Goligorsky et al., 2001). Under eNOS-uncoupling
condition, superoxide radical anion reacts with NO, resulting
in decreased NO bioavailability and increased generation of the
more potent pro-oxidant peroxynitrite causing nitrosative stress
(Förstermann and Sessa, 2012). NO is derived from L-arginine
FIGURE 1 | Enhanced renal Arg-II expression and activity in
HFD-induced obesity. (A) Immunoblotting analysis of Arg-II expression in WT
and Arg-II−/− mice with NC and HFD. (B) Bar graphs show quantification of
Arg-II protein expression and (C) activity. n = 9 for protein levels and n = 6 for
enzymatic activity, **p < 0.01 between indicated groups, n.d., not detectable.
and decrease in NO is not only important for pathogenesis of
vascular complications but also for progression of renal disease
associated with diabetes (Cheng and Harris, 2014). Among other
mechanisms, elevated activity and/or expression of arginase i.e.,
the L-arginine:ureahydrolase including arginase-I (Arg-I) and
arginase-II (Arg–II) isoenzyme, has been shown to cause eNOS-
uncoupling, resulting in increased oxidative stress in aging and
age-associated cardiovascular diseases including atherosclerosis
and type 2 diabetic vascular dysfunctions (Yepuri et al., 2012; Li
and Förstermann, 2013).
Arg-I and Arg-II are encoded by two separate genes (Sparkes
et al., 1986; Gotoh et al., 1997). Arg-I is located in cytosol,
while Arg-II is in mitochondrion (Ash, 2004). Despite different
subcellular localization, the two isoenzymes share the same
substrate L-arginine and compete with eNOS for L-arginine,
thereby decreasing intracellular L-arginine bioavailability for
production of NO (Yang and Ming, 2013). Under the condition
of L-arginine deficiency caused by elevation of either Arg-I or
Arg-II, eNOS becomes uncoupled, leading to oxidative stress and
endothelial dysfunction in cardiovascular diseases and aging (Li
and Förstermann, 2013; Yang and Ming, 2013). Hence, eNOS-
uncoupling has been shown to be an important mechanism for
oxidative stress in cardiovascular pathology.
It is well known that Arg-I is mainly expressed in hepatocytes
and is an essential enzyme involved in hepatic urea cycle for
detoxification of ammonia (Crombez and Cederbaum, 2005;
Tsang et al., 2012). In contrast, Arg-II is highly expressed in
kidney (Yang and Ming, 2014). The function of Arg-II in kidney
is, however, less well defined. There is only a limited number of
studies indicating that Arg-II is upregulated and is detrimental
for renal function in type 1 diabetes animal models (Morris
et al., 2011; Toque et al., 2013; You et al., 2013, 2014). However,
whether Arg-II is also involved in obesity-associated type 2
diabetic renal disease is not known. In contrast to these studies,
a recent study suggests that lack of Arg-II even accelerates some
of the diabetes-induced renal damages in type 1 diabetic mouse
model (Romero et al., 2013).
The aim of our study is to investigate whether Arg-II is
involved in renal damage in a diet-induced obesity mouse model.
MATERIALS AND METHODS
Materials
Antibodies against Arg-II (sc-20151), ICAM-1(sc-8439), and
VCAM-1 (sc-8304) were purchased from Santa Cruz Technology
Inc. (Dallas, USA); Antibody against tubulin (T5168), 3-
nitrotyrosine (06-284) and Periodic Acid-Schiff (PAS) staining kit
(395B) were from Sigma (Buchs, Switzerland); Antibody against
B0AT3 (Slc6a18) was produced and validated as previously
described (Romeo et al., 2006). IRDye800-conjugated anti-
rabbit IgG (926-32211) was purchased from LI-COR Biosciences
(Lincoln, USA); Alexa Fluor 680-conjugated anti-mouse IgG
(A21057), Alexa Fluor 488 conjugated-Goat anti-rabbit IgG
(H+L) secondary antibody (A-11008) and dihydroethidium
(DHE, D23107) were from Invitrogen/Thermo Fisher Scientific
(Waltham, MA USA).
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Animal Models
Arg-II−/− mice were kindly provided by Dr. William O’Brien
(Shi et al., 2001) and backcrossed to C57BL/6J for more than
10 generations (Ming et al., 2012). Genotyping was performed
by polymerase chain reaction (PCR) as previously described
(Shi et al., 2001). The WT and Arg-II−/− offsprings from
hetero/hetero cross were interbred to obtain WT and Arg-
II−/− mice, respectively, for experiments. Starting at the age
of 7 weeks, the male WT and Arg-II−/− mice were given free
access during 14 weeks to either a normal chow (NC; energy
content: 10.6% fat, 27.6% protein, and 57% carbohydrate, fiber
4.8%; Provimi Kliba NAFAG 3436; Kaiseraugst, Switzerland)
or a high fat diet (HFD, energy content: 55% fat, 21%
protein, and 24% carbohydrate; Harlan Teklad TD 93075; Horst,
Netherlands). Animals were sacrificed after 14 weeks of HFD
feeding. The kidneys were collected for histological analysis
or snap-frozen in liquid nitrogen and kept at −80◦C until
used for immunoblotting analysis and arginase activity assay or
FIGURE 2 | Arg-II is expressed in outer medulla of kidney. Confocal immunofluorescence staining of Arg-II (green) and DAPI (blue) in the kidney of WT and
Arg-II−/− mice fed either a normal chow (NC) or high fat diet (HFD). Representative images of individual staining and merged images are shown (n = 4 for each
group). OM, outer medulla; IM, inner medulla.
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cryosectioning. Due to the fact that not all the experiments can be
done with the same kidney samples for different purposes such as
immunoblotting, enzymatic activity assay, oxidative/nitrosative
stress measurement, and immunofluorescence staining, PAS
staining, etc., various series of experiments with mice on NC
and HFD were initiated. The protocol of animal handling
and experimentation was approved by the Service de la
sécurité alimentaire et des affaires vétérinaires, Etat de Fribourg,
Switzerland.
Oil Red O Staining
Cryosections of kidneys (7µm thick) were fixed with 4%
paraformaldehyde for 10 minutes followed by briefly washing
with running tap water. After quickly rinsing with 60%
isopropanol, the sections were stained with freshly prepared and
filtered Oil Red O working solution for 15 minutes, followed by
rinsing with 60% isopropanol and washing with distilled water
(Ramírez-Zacarías et al., 1992). Images were obtained with Zeiss
microscope.
FIGURE 3 | Arg-II is localized in proximal straight tubules. (A) Confocal immunofluorescence staining in consecutive sections demonstrates that Arg-II (green) is
localized in the S3 proximal straight tubules which are positive for B0AT3 (Slc6a18, red, a luminal marker of S3 proximal straight tubules) in WT mice fed either a
normal chow (NC) or high fat diet (HFD). (B) No obvious Arg-II (green) signal was detected in glomeruli (circled area) in WT mice fed either NC or HFD. Some Arg-II
signals were observed in tubules outside glomeruli (green indicated by arrows). Representative images of individual staining and merged images are shown (n = 4).
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Mesangial Expansion
3-µmparaffin sections of kidneys were stained with periodic acid
Schiff (PAS) staining kit according to manufacturer’s instruction.
All images were obtained with Zeiss microscope. The mesangial
expansion was analyzed by percentage of PAS-positive material
which occupies the mesangial matrix within the tuft. Aminimum
of 20 glomeruli in each specimen was examined.
Kidney Arginase Activity Assay
Arginase activity in kidney lysates was measured by colorimetric
determination of urea formed from L-arginine in an in vitro
activity assay as previously described (Xiong et al., 2013). Briefly,
kidney powders were lysed in lysis buffer containing 10mmol/L
Tris-HCl (pH 7.4), 0.4% Triton X-100, 10 µg/mL leupeptin,
and 0.1mmol/L phenylmethylsulfonyl fluoride (PMSF). Samples
were centrifuged at 16,200 × g at 4◦C for 10min, and protein
concentration of the supernatant was determined by the Lowry
method (Bio-Rad). For measurement of arginase activity, an
equal amount of the cell lysate was added to 50µL of Tris-HCl
(10mmol/L [pH 7.4]) containing 5mmol/L MnCl2. Arginase
was then activated by heating the mixture at 56◦C for 10min.
The hydrolysis reaction of L-arginine by arginase was conducted
by incubating the mixture containing activated arginase with
100µL of L-arginine (100mmol/L [pH 9.6]) at 37◦C for 1 h. For
colorimetric determination of urea, 1mL of chromogenic reagent
consisting of 1 volume of 3% 2,3-butanedione monoxine and
29 volumes of the acid solution mixture (H2SO4:H3PO4:H2O
1:3:7) was added, and the mixture was then heated at 100◦C
for 30min. After placing the samples in the dark for 10min
FIGURE 4 | Body weight, kidney weight/body weight ratio, and renal
lipid accumulation in obesity. Starting at the age of 7 weeks, WT and
Arg-II−/− mice were fed with HFD for 14 weeks. (A) Body weight and ratio of
kidney weight/body weight after 14 weeks HFD; n = 11 for WT mice, n = 9 for
Arg-II−/− mice. (B) Representative images of Oil Red O staining of renal
section. n = 9/group.
at room temperature, the urea concentration was determined
spectrophotometrically by the absorbance at 492 nm. The
amount of the urea produced was used as an index for arginase
activity.
Immunoblotting
Tissue lysate preparation, SDS-PAGE, and transfer of SDS
gels to Immobilon-P membranes (Millipore) were performed
as previously described (Ming et al., 2012). The resultant
membrane was first incubated with the corresponding
primary antibody overnight at 4◦C with gentle agitation
after blocking with 5% skim milk. After washing, the blot
was then further incubated with corresponding anti-mouse
(Alexa Fluor 680-conjugated) or anti-rabbit (IRDye 800-
conjugated) secondary antibodies. Signals were visualized
using the Odyssey Infrared Imaging System (LI-COR
Biosciences, USA). Quantification of the signals was performed
using NIH Image 1.62 software (US National Institutes of
Health).
Confocal Immunofluorescence Staining of
Arg-II and 3-NT
Kidneys from the WT and Arg-II−/− mice were isolated
and fixed with 3.7% paraformaldehyde and embedded in
paraffin. After deparaffinization in xylene, hydration in ethanol,
and antigen retrieval in Tris-EDTA buffer (10mmol Tris
Base, 1 mM EDTA, 0.05% Tween 20, pH 9.0) in a pressure
cooker, paraffin-embedded sections (5µm) were blocked
with 1% BSA in PBS for 60min and were then incubated
with the first antibodies (Arg-II 1:100, B0AT3 1:200, 3-
nitrotyrosine 1:200) at 4◦C overnight and subsequently with
fluorescence-labeled secondary antibodies at room temperature
for 2 h, followed by counterstaining with 300 nmol/L
DAPI (4′6-diamidino-2-phenyl-indole-dihydrochloride,
Invitrogen) for 3min. The immunofluorescence signals
were visualized under LEICA’s DIM6000 Confocal microscope.
The intensity of the fluorescence was quantified by NIH Image
J software and expressed as intensity per arbitrary unit of
area.
Detection of ROS
Detection of ROS levels was performed as described previously
(Rajapakse et al., 2011). For measurement of ROS, pre-
treated without or with NOS inhibitor L-NAME (1mmol/L,
1 h), cryosections were incubated with 5µmol/L DHE in
PBS for 30 minutes. Samples were then washed 3 times and
images were obtained with Zeiss fluorescence microscope. The
intensity of the fluorescence was quantified by NIH Image J
software.
Statistics
Data are given as mean ± SEM. In all experiments, n represents
the number of experiments or animals. Statistical analysis was
performed with Student’s unpaired t-test or analysis of variance
(ANOVA) with Tukey-test. Differences in mean values were
considered significant at two tailed P ≤ 0.05.
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RESULTS
Increased Arg-II Expression/Activity in
HFD-Induced Obesity
In the WT mice, HFD feeding significantly enhanced Arg-
II expression and arginase activity in kidney (Figure 1). As
expected, no Arg-II expression and arginase activity could be
detected in Arg-II−/− mouse kidney, demonstrating that renal
arginase activity is attributable to Arg-II isoenzyme. Confocal
microscopic immunofluorescence staining showed that Arg-
II was mainly expressed in tubules of outer medulla, which
is increased in the HFD fed WT mice (Figure 2). Further
experiments in consecutive sections demonstrated that Arg-II
is expressed in the tubule cells which are positive for B0AT3
(Slc6a18), a luminal marker of S3 straight segment of proximal
tubules (Figure 3A). No significant signal of Arg-II in the
glomeruli could be detected either in mice fed NC or HFD
(Figure 3B).
Arg-II-Deficiency Protects Against Ectopic
Renal Lipid Accumulation in Obesity
No difference in body weight and kidney weight/body weight
ratio was observed between WT and Arg-II−/− mice fed
HFD (Figure 4A). Lipid accumulation in kidney was frequently
observed in the obese WT mice, whereas this was not the case in
the Arg-II−/− mice (Figure 4B). The results indicate that Arg-
II deficiency protects against ectopic renal lipid accumulation in
diet-induced obesity.
Arg-II-Deficiency Prevents Renal Oxidative
Oxygen Species (ROS) Generation,
Adhesion Molecule Expression and
Glomerulus Mesangial Expansion
In the WT mice fed HFD, there was a significant higher level of
ROS generation (DHE staining) in the glomeruli as compared to
the Arg-II−/− mice on HFD (Figure 5). Interestingly, the ROS
generation was inhibited by the NOS inhibitor L-NAME (10−3
mol/L, Figure 5), demonstrating NOS-uncoupling in obesity
kidney. Similarly, peroxynitrite levels as demonstrated by 3-NT
staining were increased in HFD fed WT mice and this obesity-
induced increase in peroxynitrite was prevented in the Arg-II−/−
mice (Figure 6). Moreover, Arg-II−/− mice revealed decreased
mesangial expansion (Figure 7) and lower levels of renal ICAM-1
and VCAM-1 as demonstrated by immunoblotting (Figure 8).
DISCUSSION
In this study, we demonstrate that HFD-induced obesity is
associated with renal injury markers, i.e., oxidative stress,
as assessed by increased DHE staining and peroxynitrite
levels, enhanced levels of inflammatory adhesion molecules,
mesangial expansion, and more frequent lipid accumulation in
kidney, which are characteristics of diabetic kidney disease as
demonstrated by several studies in the same animal model (Lal
et al., 2000; DeRubertis et al., 2004; Menini et al., 2006; Fioretto
et al., 2008; Deji et al., 2009; Declèves et al., 2011; Cui et al., 2013).
FIGURE 5 | Arg-II-deficiency decreases renal ROS production in
obesity. (A) Immuno-fluorescence confocal microscopy showing O−2 level in
glomerulus detected by DHE staining (red). Kidney cryosections were
pre-treated with or without NOS inhibitor L-NAME (1 mmol/L, 1 h) prior to the
DHE staining. Nuclei were counter stained by DAPI (blue). (B) Bar graphs
show quantification of DHE signals. n = 4, *p < 0.05, **p < 0.01, ***p < 0.001
between the indicated groups.
These renal alterations are important mechanisms leading to end
stage renal disease (ESRD) associated with obesity. Importantly,
our current study provides novel evidence demonstrating that
diet-induced obesity enhances renal Arg-II level and that genetic
ablation of Arg-II protects mice from the renal pathological
changes in diet-induced obesity.
Role of Arg-II in Diabetic Kidney Disease
It is well known that kidney expresses abundant Arg-II (Morris
et al., 2011). The physiological role of Arg-II in renal function
is not known. Some studies demonstrate that Arg-II may
participate in pathogenesis of renal diseases associated with
type 1 diabetes in mouse models. For example, pharmacological
inhibition of Arg-II in spontaneously diabetic Ins2Akita mice
or streptozotocin (STZ)-induced diabetic Dilute Brown Agouti
(DBA) mice is able to attenuate renal injuries, including
albuminuria and kidney macrophage infiltration (Morris et al.,
2011; You et al., 2013). Also, mice with genetic Arg-II deficiency
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FIGURE 6 | Arg-II deficiency prevents obesity-associated increase in renal peroxynitrite formation. Confocal immunofluorescence staining of 3-NT (green)
and DAPI (blue) in the kidney of WT and Arg-II−/− mice fed either normal chow (NC) or high fat diet (HFD). Representative images of individual staining and merged
images are shown (n = 4). Quantifications of 3-NT signals are shown in the bar graphs. *p < 0.05, **p < 0.01.
are protected from renal injuries in STZ-induced diabetes
(Morris et al., 2011). These studies suggest an important role of
Arg-II in type 1 diabetic renal disease. However, another group
demonstrates opposite effects, i.e., Arg-II deficiency accelerates
some of the STZ-induced renal damages in mice (Romero et al.,
2013). The discrepancy between the two studies is not clear. In
accordance with the study in type 1 diabetic mouse model in
which renal arginase activity is increased (Morris et al., 2011),
we also demonstrate in the current study an increase in Arg-II
levels and arginase activity in kidney of the obesity-associated
type 2 mouse model. Since Arg-I is not detectable in the kidney,
the increase in arginase activity in kidney is solely attributable to
Arg-II.
Arg-II Is Mainly Localized in the Straight
Segment of Proximal Tubules
In line with the observation in kidney, we have previously
shown that in the same diet-induced obesity mouse model,
Arg-II is upregulated in other cells such as macrophages
and vascular endothelial cells (Yu et al., 2014). The increase
in Arg-II in macrophages under HFD feeding promotes
pro-inflammatory responses, contributing to obesity-associated
glucose intolerance, insulin resistance, and nonalcoholic fatty
liver diseases (NAFLD) as well as atherogenesis (Ming et al.,
2012; Liu et al., 2016). In kidney, we demonstrate in this study
that Arg-II is mainly expressed in the S3 straight segment
of the proximal tubules as demonstrated by expression in
the B0AT3 positive cells. In the glomeruli, however, no Arg-
II signal could be detected by immunofluorescence analysis.
At this stage, the mechanisms of upregulation of Arg-II
in kidney are not known. In the vascular cells, Arg-II
upregulation involves activation of mTOR/S6K1 and p38mapk
signaling pathways (Yepuri et al., 2012; Xiong et al., 2013,
2014; Wu et al., 2015). Whether these mechanisms are also
involved in the obesity-associated renal injury remains to be
investigated.
Arg-II Causes Renal Oxidative Stress
through NOS-Uncoupling in Obesity
It has been shown that Arg-II upregulation in blood vessels
of obesity mice causes endothelial dysfunction and eNOS-
uncoupling, leading to decrease in NO production and
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FIGURE 7 | Arg-II-deficiency protects against mesangial expansion in
obesity. (A) PAS staining (magenta) of paraffin-embedded kidney sections
shows decreased mesangial expansion in Arg-II−/− mice as compared to WT
mice on HFD. Nuclei were counter stained by hematoxylin (blue). Kidney from
a WT mice on NC diet was used as a control. (B) Bar graphs show
quantification of mesangial expansion. n = 5, ***p < 0.001 vs. WT-HFD group.
increase in superoxide radical anion levels (Yu et al., 2014).
Importantly, eNOS-uncoupling has been reported to contribute
to the pathogenesis of diabetic nephropathy (Prabhakar et al.,
2007). In line with these findings, we demonstrate increased
expression levels and activity of Arg-II in kidney of diet-
induced obesity mice, which causes renal oxidative stress
due to NOS-uncoupling, since the NOS inhibitor, L-NAME,
reduces ROS levels as assessed by DHE staining. NO can
react with superoxide radical anion to produce peroxynitrite
which is able to cause nitration of tyrosine residues of proteins,
i.e., nitrosative stress (Förstermann and Sessa, 2012). The
modification of proteins at tyrosine residues often leads to
functional decline of enzyme activity. It has been shown that
the mitochondrial antioxidant enzyme manganese superoxide
dismutase (MnSOD) is modified by the nitrosative stress and
contains nitrotyrosine in angiotensin II-induced hypertensive rat
kidney, which may facilitate the oxidative/nitrosative stress and
renal injury (Xu et al., 2006). Various studies provide evidence
for the important role of oxidative/nitrosative stress in renal
injury and disease progression (Ratliff et al., 2016; Sharma,
2016). In support of this finding, the oxidative/nitrosative
stress as assessed by increased levels of superoxide radical
anion and 3-NT in kidney of obesity mice is prevented
in Arg-II−/− animals despite no changes in body weight
and kidney weight/body weight ratio. It is to mention that
myeloperoxidase and other peroxidases are also involved
in nitrotyrosine formation (Gaut et al., 2002). Functional
roles of these enzymes in renal nitrosative stress in the
mouse model could not be excluded and require further
investigation.
FIGURE 8 | Arg-II-deficiency reduces adhesion molecule levels in the
kidney in obesity. (A) Immunoblotting analysis of VCAM-1 and ICAM-I
expression in the kidney of WT and Arg-II−/− mice fed HFD. (B) Bar graphs
show quantification of VCAM-1 and ICAM-I expression. n = 4, *p < 0.05
between indicated groups.
Oxidative stress derived from eNOS-uncoupling caused by
Arg-II is causatively involved in adhesion molecule expression
in the endothelial cells (Yepuri et al., 2012). In line with
this observation, our present study demonstrates that Arg-II
and adhesion molecule expression in kidney are upregulated
in obesity and that Arg-II deficiency reduces oxidative stress,
decreases VCAM-1 and ICAM-1 levels in kidney of the obesity
mouse model. Together, these results suggest that Arg-II indeed
plays an important role in obesity-associated renal damage
involving NOS-uncoupling. Since kidney expresses eNOS, iNOS,
and nNOS (Prabhakar et al., 2007) and decreased renal NO
bioavailability is linked to diabetic renal disease (Erdely et al.,
2004; Prabhakar, 2005), the question whether each of these
isoenzymes are uncoupled in kidney of obesity mice remains
to be investigated. Another important question which remains
to be investigated is how the proximal tubule straight segments
interact with glomerulus cells and participate in diabetic renal
injury.
Role of Arg-II in Renal Lipid Accumulation
in Obesity
It is important to point out that the Arg-II−/− mice are
protected from whole body glucose intolerance with improved
insulin sensitivity and less NAFLD on HFD (Liu et al.,
2016). Similar to the liver, we also found a decreased renal
lipid accumulation in kidney as shown in our current
study. The renal lipid accumulation in type 2 diabetes is
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well described in humans and animal models, which is
considered as an important contributor to progression of
diabetic nephropathy in obesity (Jiang et al., 2005). The
underlying mechanisms are attributable to the increased
expression of the transcriptional factors SREBP-1c, the
master regulator of lipogenesis and suppressed renal lipolysis
(Jiang et al., 2005; Kume et al., 2007). The results of our
current study suggest an important role of Arg-II in obesity-
associated renal diseases. It remains to be investigated how
important the renal Arg-II is in the development of obesity-
associated kidney damage. For this purpose, renal specific
Arg-II knockout mouse model shall be generated in the
future.
CONCLUSIONS
We demonstrate that Arg-II deficiency in mouse protects against
obesity-associated renal alterations. The results suggest that
targeting Arg-II may represent a promising therapeutic strategy
for diabetic nephropathy.
AUTHOR CONTRIBUTIONS
JH, AR, and YX: acquisition, analysis, or interpretation of data for
the work; preparation of figures; critically revised the manuscript
for important intellectual content. XM and ZY: design of
the work; analyzed and interpreted primary research papers,
drafted the manuscript and critically revised the manuscript
for important intellectual content. FV: generated and validated
antibody against B0AT3 and critically revised the manuscript
for important intellectual content. JM: interpreted primary
research papers, critically revised the manuscript for important
intellectual content. All authors agree to be accountable for the
content of the work.
FUNDING
This work was supported by the Swiss National Science
Foundation (31003A_159582/1), Swiss Heart Foundation, and
National Centre of Competence in Research Program (NCCR-
Kidney.CH).
REFERENCES
Ash, D. E. (2004). Structure and function of arginases. J. Nutr. 134, 2760S–2764S.
Cheng, H., and Harris, R. C. (2014). Renal endothelial dysfunction in diabetic
nephropathy. Cardiovasc. Hematol. Disord Drug Targets 14, 22–33. doi: 10.
2174/1871529X14666140401110841
Cheng, H., Wang, H., Fan, X., Paueksakon, P., and Harris, R. C. (2012).
Improvement of endothelial nitric oxide synthase activity retards the
progression of diabetic nephropathy in db/db mice. Kidney Int. 82, 1176–1183.
doi: 10.1038/ki.2012.248
Collaboration, N. C. D. R. F. (2016). Worldwide trends in diabetes since 1980: a
pooled analysis of 751 population-based studies with 4.4 million participants.
Lancet 387, 1513–1530. doi: 10.1016/S0140-6736(16)00618-8
Collins, A. J., Foley, R. N., Herzog, C., Chavers, B., Gilbertson, D., Herzog, C., et al.
(2013). US renal data system 2012 annual data report. Am. J. Kidney Dis. 61,
e1–476. doi: 10.1053/j.ajkd.2012.11.031
Crombez, E. A., and Cederbaum, S. D. (2005). Hyperargininemia due to liver
arginase deficiency. Mol. Genet. Metab. 84, 243–251. doi: 10.1016/j.ymgme.
2004.11.004
Cui, W., Maimaitiyiming, H., Qi, X., Norman, H., and Wang, S. (2013).
Thrombospondin 1 mediates renal dysfunction in a mouse model of high-fat
diet-induced obesity. Am. J. Physiol. Renal Physiol. 305, F871–F880. doi: 10.
1152/ajprenal.00209.2013
Declèves, A. E., Mathew, A. V., Cunard, R., and Sharma, K. (2011). AMPK
mediates the initiation of kidney disease induced by a high-fat diet. J. Am. Soc.
Nephrol. 22, 1846–1855. doi: 10.1681/ASN.2011010026
Deji, N., Kume, S., Araki, S., Soumura, M., Sugimoto, T., and Isshiki, K., et al.
(2009). Structural and functional changes in the kidneys of high-fat diet-
induced obese mice. Am. J. Physiol. Renal Physiol. 296, F118–F126. doi: 10.
1152/ajprenal.00110.2008
DeRubertis, F. R., Craven, P. A., Melhem, M. F., and Salah, E. M. (2004).
Attenuation of renal injury in db/db mice overexpressing superoxide
dismutase: evidence for reduced superoxide-nitric oxide interaction. Diabetes
53, 762–768. doi: 10.2337/diabetes.53.3.762
Erdely, A., Freshour, G., Maddox, D. A., Olson, J. L., Samsell, L., and Baylis, C.
(2004). Renal disease in rats with type 2 diabetes is associated with decreased
renal nitric oxide production.Diabetologia 47, 1672–1676. doi: 10.1007/s00125-
004-1509-1
Fioretto, P., Caramori, M. L., and Mauer, M. (2008). The kidney in diabetes:
dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007.
Diabetologia 51, 1347–1355. doi: 10.1007/s00125-008-1051-7
Förstermann, U., and Sessa, W. C. (2012). Nitric oxide synthases: regulation
and function. Eur. Heart J. 33, 829–837. doi: 10.1093/eurheartj/
ehr304
Gaut, J. P., Byun, J., Tran, H. D., Lauber, W. M., Carroll, J. A., and Hotchkiss, R.
S., et al. (2002). Myeloperoxidase produces nitrating oxidants in vivo. J. Clin.
Invest. 109, 1311–1319. doi: 10.1172/JCI0215021
Goligorsky, M. S., Chen, J., and Brodsky, S. (2001). Workshop: endothelial
cell dysfunction leading to diabetic nephropathy: focus on nitric oxide.
Hypertension 37, 744–748. doi: 10.1161/01.HYP.37.2.744
Gotoh, T., Araki, M., and Mori, M. (1997). Chromosomal localization of the
human arginase II gene and tissue distribution of its mRNA. Biochem. Biophys.
Res. Commun. 233, 487–491. doi: 10.1006/bbrc.1997.6473
Jiang, T., Wang, Z., Proctor, G., Moskowitz, S., Liebman, S. E., and Rogers, T.,
et al. (2005). Diet-induced obesity in C57BL/6Jmice causes increased renal lipid
accumulation and glomerulosclerosis via a sterol regulatory element-binding
protein-1c-dependent pathway. J. Biol. Chem. 280, 32317–32325. doi: 10.1074/
jbc.M500801200
Kume, S., Uzu, T., Araki, S., Sugimoto, T., Isshiki, K., and Chin-Kanasaki, M., et al.
(2007). Role of altered renal lipidmetabolism in the development of renal injury
induced by a high-fat diet. J. Am. Soc. Nephrol. 18, 2715–2723. doi: 10.1681/
ASN.2007010089
Lal, M. A., Körner, A., Matsuo, Y., Zelenin, S., Cheng, S. X., and Jaremko, G., et al.
(2000). Combined antioxidant and COMT inhibitor treatment reverses renal
abnormalities in diabetic rats. Diabetes 49, 1381–1389. doi: 10.2337/diabetes.
49.8.1381
Li, H., and Förstermann, U. (2013). Uncoupling of endothelial NO synthase
in atherosclerosis and vascular disease. Curr. Opin. Pharmacol. 13, 161–167.
doi: 10.1016/j.coph.2013.01.006
Liu, C., Rajapakse, A. G., Riedo, E., Fellay, B., Bernhard, M. C., and Montani, J.
P., et al. (2016). Targeting arginase-II protects mice from high-fat-diet-induced
hepatic steatosis through suppression of macrophage inflammation. Sci. Rep.
6:20405. doi: 10.1038/srep20405
Menini, S., Amadio, L., Oddi, G., Ricci, C., Pesce, C., and Pugliese, F., et al. (2006).
Deletion of p66Shc longevity gene protects against experimental diabetic
glomerulopathy by preventing diabetes-induced oxidative stress. Diabetes 55,
1642–1650. doi: 10.2337/db05-1477
Ming, X. F., Rajapakse, A. G., Yepuri, G., Xiong, Y., Carvas, J. M., and
Ruffieux, J., et al. (2012). Arginase II Promotes macrophage inflammatory
responses through mitochondrial reactive oxygen species, contributing to
insulin resistance and atherogenesis. J. Am. Heart Assoc. 1:e000992. doi: 10.
1161/JAHA.112.000992
Frontiers in Physiology | www.frontiersin.org 9 November 2016 | Volume 7 | Article 560
Huang et al. Arginase-II and Obesity-Associated Renal Damage
Morris, S. M. Jr., Gao, T., Cooper, T. K., Kepka-Lenhart, D., and Awad, A. S. (2011).
Arginase-2mediates diabetic renal injury.Diabetes 60, 3015–3022. doi: 10.2337/
db11-0901
Nakagawa, T., Tanabe, K., Croker, B. P., Johnson, R. J., Grant, M. B., Kosugi,
T., et al. (2011). Endothelial dysfunction as a potential contributor in diabetic
nephropathy. Nat. Rev. Nephrol. 7, 36–44. doi: 10.1038/nrneph.2010.152
Prabhakar, S. S. (2005). Pathogenic role of nitric oxide alterations in diabetic
nephropathy. Curr. Diab. Rep. 5, 449–454. doi: 10.1007/s11892-005-0054-8
Prabhakar, S., Starnes, J., Shi, S., Lonis, B., and Tran, R. (2007). Diabetic
nephropathy is associated with oxidative stress and decreased renal nitric oxide
production. J. Am. Soc. Nephrol. 18, 2945–2952. doi: 10.1681/ASN.2006080895
Rajapakse, A. G., Yepuri, G., Carvas, J. M., Stein, S., Matter, C. M., and Scerri,
I., et al. (2011). Hyperactive S6K1 mediates oxidative stress and endothelial
dysfunction in aging: inhibition by resveratrol. PLoS ONE 6:e19237. doi: 10.
1371/journal.pone.0019237
Ramírez-Zacarías, J. L., Castro-Muñozledo, F., and Kuri-Harcuch, W.
(1992). Quantitation of adipose conversion and triglycerides by staining
intracytoplasmic lipids with Oil red O. Histochemistry 97, 493–497. doi: 10.
1007/BF00316069
Ratliff, B. B., Abdulmahdi, W., Pawar, R., and Wolin, M. S. (2016). Oxidant
mechanisms in renal injury and disease. Antioxid. Redox Signal. 25, 119–146.
doi: 10.1089/ars.2016.6665
Romeo, E., Dave, M. H., Bacic, D., Ristic, Z., Camargo, S. M., Loffing, J., et al.
(2006). Luminal kidney and intestine SLC6 amino acid transporters of B0AT-
cluster and their tissue distribution in Mus musculus. Am. J. Physiol. Renal
Physiol. 290, F376–F383. doi: 10.1152/ajprenal.00286.2005
Romero, M. J., Yao, L., Sridhar, S., Bhatta, A., Dou, H., and Ramesh, G., et al.
(2013). l-citrulline protects from kidney damage in type 1 diabetic mice. Front.
Immunol. 4:480. doi: 10.3389/fimmu.2013.00480
Sharma, K. (2016). Obesity and diabetic kidney disease: role of oxidant stress and
redox balance. Antioxid. Redox Signal. 25, 208–216. doi: 10.1089/ars.2016.6696
Shi, O., Morris, S. M. Jr., Zoghbi, H., Porter, C. W., and O’Brien, W. E. (2001).
Generation of a mouse model for arginase II deficiency by targeted disruption
of the arginase II gene.Mol. Cell. Biol. 21, 811–813. doi: 10.1128/MCB.21.3.811-
813.2001
Sparkes, R. S., Dizikes, G. J., Klisak, I., Grody, W. W., Mohandas, T., and
Heinzmann, C., et al. (1986). The gene for human liver arginase (ARG1) is
assigned to chromosome band 6q23. Am. J. Hum. Genet. 39, 186–193.
Toque, H. A., Nunes, K. P., Yao, L., Xu, Z., Kondrikov, D., Su, Y., et al. (2013).
Akita spontaneously type 1 diabetic mice exhibit elevated vascular arginase
and impaired vascular endothelial and nitrergic function. PLoS ONE 8:e72277.
doi: 10.1371/journal.pone.0072277
Tsang, J. P., Poon, W. L., Luk, H. M., Fung, C. W., Ching, C. K., Mak, C.
M., et al. (2012). Arginase deficiency with new phenotype and a novel
mutation: contemporary summary. Pediatr. Neurol. 47, 263–269. doi: 10.1016/
j.pediatrneurol.2012.06.012
Wang, C. H., Li, F., Hiller, S., Kim, H. S., Maeda, N., Smithies, O., et al. (2011). A
modest decrease in endothelial NOS in mice comparable to that associated with
human NOS3 variants exacerbates diabetic nephropathy. Proc. Natl. Acad. Sci.
U.S.A. 108, 2070–2075. doi: 10.1073/pnas.1018766108
Wu, Z., Yu, Y., Liu, C., Xiong, Y., Montani, J. P., Yang, Z., et al. (2015). Role of p38
mitogen-activated protein kinase in vascular endothelial aging: interaction with
Arginase-II and S6K1 signaling pathway. Aging (Albany. NY). 7, 70–81. doi: 10.
18632/aging.100722
Xiong, Y., Yepuri, G., Forbiteh, M., Yu, Y., Montani, J. P., Yang, Z., et al.
(2014). ARG2 impairs endothelial autophagy through regulation of MTOR
and PRKAA/AMPK signaling in advanced atherosclerosis. Autophagy 10,
2223–2238. doi: 10.4161/15548627.2014.981789
Xiong, Y., Yu, Y., Montani, J. P., Yang, Z., and Ming, X. F. (2013). Arginase-II
induces vascular smooth muscle cell senescence and apoptosis through p66Shc
and p53 independently of its l-arginine ureahydrolase activity: implications for
atherosclerotic plaque vulnerability. J. Am. Heart Assoc. 2:e000096. doi: 10.
1161/JAHA.113.000096
Xu, S., Ying, J., Jiang, B., Guo, W., Adachi, T., Sharov, V., et al. (2006). Detection
of sequence-specific tyrosine nitration of manganese SOD and SERCA in
cardiovascular disease and aging. Am. J. Physiol. Heart Circ. Physiol. 290,
H2220–H2227. doi: 10.1152/ajpheart.01293.2005
Yang, Z., and Ming, X. F. (2013). Arginase: the emerging therapeutic target for
vascular oxidative stress and inflammation. Front. Immunol. 4:149. doi: 10.
3389/fimmu.2013.00149
Yang, Z., and Ming, X. F. (2014). Functions of arginase isoforms in macrophage
inflammatory responses: impact on cardiovascular diseases and metabolic
disorders. Front. Immunol. 5:533. doi: 10.3389/fimmu.2014.00533
Yepuri, G., Velagapudi, S., Xiong, Y. Y., Rajapakse, A. G., Montani, J. P., Ming,
X. F., et al. (2012). Positive crosstalk between arginase-II and S6K1 in vascular
endothelial inflammation and aging. Aging Cell 11, 1005–1016. doi: 10.1111/
acel.12001
You, H., Gao, T., Cooper, T. K., Morris, S. M. Jr., and Awad, A. S. (2013). Arginase
inhibition mediates renal tissue protection in diabetic nephropathy by a nitric
oxide synthase 3-dependent mechanism. Kidney Int. 84, 1189–1197. doi: 10.
1038/ki.2013.215
You, H., Gao, T., Cooper, T. K., Morris, S. M. Jr., and Awad, A. S. (2014). Diabetic
nephropathy is resistant to oral L-arginine or L-citrulline supplementation.Am.
J. Physiol. Renal Physiol. 307, F1292–F1301. doi: 10.1152/ajprenal.00176.2014
Yu, Y., Rajapakse, A. G., Montani, J. P., Yang, Z., and Ming, X. F. (2014). p38
mitogen-activated protein kinase is involved in arginase-II-mediated eNOS-
Uncoupling in Obesity. Cardiovasc. Diabetol. 13:113. doi: 10.1186/s12933-014-
0113-z
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Huang, Rajapakse, Xiong, Montani, Verrey, Ming and Yang.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Physiology | www.frontiersin.org 10 November 2016 | Volume 7 | Article 560
